MicroRNAs in cardiac hypertrophy: Angels or devils

Wiley Interdisciplinary Reviews: RNA

Volumn 2, Issue 1, 2011, Pages 124-134

  Ding, Su Ling ^a   Zhou, Lu Yu ^a   Li, Pei Feng ^a  

^a INSTITUTE OF ZOOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EXPORTIN 5; MICRORNA; MICRORNA 1; MICRORNA 106A; MICRORNA 125B; MICRORNA 133; MICRORNA 153; MICRORNA 184; MICRORNA 18B; MICRORNA 195; MICRORNA 199A; MICRORNA 19B; MICRORNA 200A; MICRORNA 208; MICRORNA 21; MICRORNA 210; MICRORNA 211; MICRORNA 214; MICRORNA 217; MICRORNA 221; MICRORNA 222; MICRORNA 23A; MICRORNA 23B; MICRORNA 24; MICRORNA 26; MICRORNA 27A; MICRORNA 27B; MICRORNA 2OB; MICRORNA 424; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AORTA STENOSIS; CONGESTIVE CARDIOMYOPATHY; DOWN REGULATION; GENE EXPRESSION; GENE FUNCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; ISCHEMIC CARDIOMYOPATHY; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; BIOLOGICAL MODEL; CARDIOMEGALY; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; METABOLISM; METHODOLOGY; PHYSIOLOGY;

ANIMALS; CARDIOMEGALY; GENE EXPRESSION REGULATION; GENE THERAPY; HUMANS; MICRORNAS; MODELS, BIOLOGICAL;

EID: 84858311947     PISSN: 17577004     EISSN: 17577012     Source Type: Journal    
DOI: 10.1002/wrna.61     Document Type: Review

References (78)

1. Juenger J, Schellberg D, Kraemer S, Haunstetter A, Zugck C, Herzog W, Haass M. Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables. Heart 2002, 87:235-241.
2. Meijs MFL, de Windt LJ, de Jonge N, Cramer MJM, Bots ML, Mali W, Doevendans PA. Left ventricular hypertrophy: a shift in paradigm. Curr Med Chem 2007, 14:157-171.
3. Thum T, Catalucci D, Bauersachs J. MicroRNAs: novel regulators in cardiac development and disease. Cardiovasc Res 2008, 79:562-570.
4. McKinsey TA, Olson EN. Toward transcriptional therapies for the failing heart: chemical screens to modulate genes. J Clin Invest 2005, 115:538-546.
5. van Rooij E, Marshall WS, Olson EN. Toward microRNA-based therapeutics for heart disease: the sense in antisense. Circ Res 2008, 103:919-928.
6. Pauley KM, Eystathioy T, Jakymiw A, Hamel JC, Fritzler MJ, Chan EKL. Formation of GW bodies is a consequence of microRNA genesis. EMBO Rep 2006, 7:904-910.
7. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003, 115:787-798.
8. Kim VN, Han J, Siomi MC. Biogenesis of small RNAs in animals. Mol Cell Biol 2009, 10:126-139.
9. Han JJ, Lee Y, Yeom KH, Nam JW, Heo I, Rhee JK, Sohn SY, Cho YJ, Zhang BT, Kim VN, et al. Molecular basis for the recognition of primary microRNAs by the Drosha-DGCR8 complex. Cell 2006, 125:887-901.
10. Winter J, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009, 11: 228-234.
11. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell 2003, 115:505.
12. Okamura K, Hagen JW, Duan H, Tyler DM, Lai EC. The mirtron pathway generates microRNA-class regulatory RNAs in Drosophila. Cell 2007, 130:89-100.
13. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75:843-854.
14. Marsit CJ, Eddy K, Kelsey KT. MicroRNA responses to cellular stress. Cancer Res 2006, 66:10843-10848.
15. Ikeda S, Kong SW, Lu J, Bisping E, Zhang H, Allen PD, Golub TR, Pieske B, Pu WT. Altered microRNA expression in human heart disease. Physiol Genomics 2007, 31:367-373.
16. Prasad SVN, Duan ZH, Gupta MK, Surampudi VSK, Volinia S, Calin GA, Liu CG, Kotwal A, Moravec CS, Starling RC, et al. Unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. J Biol Chem 2009, 284:27487-27499.
17. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans PA, Mummery CL, Borlak J, Haverich A, et al. MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation 2007, 116:258-267.
18. Zhao Y, Samal E, Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 2005, 436: 214-220.
19. Wagner M, Mascareno E, Siddiqui MAQ. Cardiac hypertrophy: signal transduction, transcriptional adaptation, and altered growth control. Ann N Y Acad Sci 1999, 874:1-10.
20. Bernstein E, Kim SY, Carmell MA, Murchison EP, Alcorn H, Li MZ, Mills AA, Elledge SJ, Anderson KV, Hannon GJ, et al. Dicer is essential for mouse development. Nat Genet 2003, 35:215-217.
21. Yang WJ, Yang DD, Na SQ, Sandusky GE, Zhang Q, Zhao GS. Dicer is required for embryonic angiogenesis during mouse development. J Biol Chem 2005, 280:9330-9335.
22. Chen JF, Murchison EP, Tang R, Callis TE, Tatsuguchi M, Deng Z, Rojas M, Hammond SM, Schneider MD, Selzman CH, et al. Targeted deletion of Dicer in the heart leads to dilated cardiomyopathy and heart failure. Proc Natl Acad Sci U S A 2008, 105:2111-2116.
23. Martins P, Bourajjaj M, Gladka M, Kortland M, van Oort RJ, Pinto YM, Molkentin JD, De Windt LJ. Conditional Dicer gene deletion in the postnatal myocardium provokes spontaneous cardiac remodeling. Circulation 2008, 118:1567-1576.
24. McCarthy JJ, Esser KA. MicroRNA-1 and microRNA-133a expression are decreased during skeletal muscle hypertrophy. J Appl Physiol 2007, 102:306-313.
25. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, Hammond SM, Joshua-Tor L, Hannon GJ. Argonaute2 is the catalytic engine of mammalian RNAi. Science 2004, 305:1437.
26. Kalsotra A, Wang K, Li PF, Cooper TA. MicroRNAs coordinate an alternative splicing network during mouse postnatal heart development. Genes Dev 2010, 24:653-658.
27. Cheng YH, Ji RR, Yue JM, Yang J, Liu XJ, Chen H, Dean DB, Zhang CX. MicroRNAs are aberrantly expressed in hypertrophic heart-Do they play a role in cardiac hypertrophy? Am J Pathol 2007, 170:1831-1840.
28. Tatsuguchi M, Seok HY, Callis TE, Thomson JM, Chen JF, Newman M, Rojas M, Hammond SM, Wang DZ. Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol 2007, 42:1137-1141.
29. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, Richardson JA, Olson EN. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 2006, 103:18255-18260.
30. Yalçin F, Muderrisoglu H, Korkmaz ME, Ozin B. Do variable age-related secondary factors affect ventricular geometry in hypertrophic cardiomyopathy? Adv Ther 2002, 19:253-257.
31. Harris KS, Zhang Z, McManus MT, Harfe BD, Sun X. Dicer function is essential for lung epithelium morphogenesis. Proc Natl Acad Sci U S A 2006, 103:2208-2213.
32. van Rooij E, Sutherland LB, Qi XX, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 2007, 316:575-579.
33. Callis TE, Pandya K, Seok HY, Tang RH, Tatsuguchi M, Huang ZP, Chen JF, Deng Z, Gunn B, Shumate J, et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest 2009, 119: 2772-2786.
34. Cheng YH, Ji RR, Yue JM, Yang J, Liu XJ, Chen H, Dean DB, Zhang CX. MicroRNAs are aberrantly expressed in hypertrophic heart: Do they play a role in cardiac hypertrophy? Am J Pathol 2007, 170:1831-1840.
35. Satoh M, Minami Y, Takahashi Y, Tabuchi T, Nakamura M. Expression of microRNA-208 is associated with adverse clinical outcomes in human dilated cardiomyopathy. J Card Fail 2010, 16:404-410.
36. Abraham WT, Gilbert EM, Lowes BD, Minobe WA, Larrabee P, Roden RL, Dutcher D, Sederberg J, Lindenfeld JA, Wolfel EE, et al. Coordinate changes in myosin heavy chain isoform gene expression are selectively associated with alterations in dilated cardiomyopathy phenotype. Mol Med 2002, 8:750-760.
37. Lowes BD, Minobe W, Abraham WT, Rizeq MN, Bohlmeyer TJ, Quaife RA, Roden RL, Dutcher DL, Robertson AD, Voelkel NF, et al. Changes in gene expression in the intact human heart-downregulation of alpha-myosin heavy chain in hypertrophied, failing ventricular myocardium. J Clin Invest 1997, 100:2315-2324.
38. Nakao K, Minobe W, Roden R, Bristow MR, Leinwand LA. Myosin heavy chain gene expression in human heart failure. J Clin Invest 1997, 100:2362-2370.
39. Weiss A, Leinwand LA. The mammalian myosin heavy chain gene family. Annu Rev Cell Dev Biol 1996, 12: 417-439.
40. Ito M, Roeder RG. The TRAP/SMCC/Mediator complex and thyroid hormone receptor function. Trends Endocrinol Metab 2001, 12:127-134.
41. Morkin E. Control of cardiac myosin heavy chain gene expression. Microsc Res Tech 2000, 50:522-531.
42. Lin Z, Murtaza I, Wang K, Jiao J, Gao J, Li PF. MiR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. Proc Natl Acad Sci U S A 2009, 106: 12103-12108.
43. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H. Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. Endocrinology 2000, 141: 1901-1904.
44. Tse J, Powell JR, Baste CA, Priest RE, Kuo JF. Isoproterenol-induced cardiac hypertrophy: modifications in characteristics of beta-adrenergic receptor, adenylate cyclase, and ventricular contraction. Endocrinology 1979, 105:246-255.
45. Clipstone NA, Crabtree GR. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 1992, 357:695-697.
46. Molkentin JD. Calcineurin and beyond: cardiac hypertrophic signaling. Circ Res 2000, 87:731-738.
47. Wilkins BJ, Molkentin JD. Calcineurin and cardiac hypertrophy: Where have we been? Where are we going? J Physiol 2002, 541:1-8.
48. Willis MS, Ike C, Li L, Wang DZ, Glass DJ, Patterson C. Muscle ring finger 1, but not muscle ring finger 2, regulates cardiac hypertrophy in vivo. Circ Res 2007, 100: 456-459.
49. Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, Conlon FL, Wang DZ. The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet 2006, 38:228-233.
50. Carè A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML, Segnalini P, Gu Y, Dalton ND, et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 2007, 13:613-618.
51. Sayed D, Hong C, Chen IY, Lypowy J, Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 2007, 100:416-424.
52. Brown JH, Del Re DP, Sussman MA. The Rac and Rho hall of fame: a decade of hypertrophic signaling hits. Circ Res 2006, 98:730-742.
53. Ke Y, Wang L, Pyle WG, de Tombe PP, Solaro RJ. Intracellular localization and functional effects of P21-activated kinase-1 (Pak1) in cardiac myocytes. Circ Res 2004, 94:194-200.
54. Sucharov C, Bristow MR, Port JD. miRNA expression in the failing human heart: functional correlates. J Mol Cell Cardiol 2008, 45:185-192.
55. van Rooij E, Olson EN. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 2007, 117:2369-2376.
56. Zhao Y, Ransom JF, Li A, Vedantham V, von Drehle M, Muth AN, Tsuchihashi T, McManus MT, Schwartz RJ, Srivastava D, et al. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 2007, 129:303-317.
57. Ikeda S, He A, Kong SW, Lu J, Bejar R, Bodyak N, Lee KH, Ma Q, Kang PM, Golub TR, et al. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol 2009, 29:2193-2204.
58. Obata K, Nagata K, Iwase M, Odashima M, Nagasaka T, Izawa H, Murohara T, Yamada Y, Yokota M. Overexpression of calmodulin induces cardiac hypertrophy by a calcineurin-dependent pathway. Biochem Biophys Res Commun 2005, 338:1299-1305.
59. Zhang CL, McKinsey TA, Chang SR, Antos CL, Hill JA, Olson EN. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 2002, 110:479-488.
60. Morin S, Charron F, Robitaille L, Nemer M. GATA-dependent recruitment of MEF2 proteins to target promoters. EMBO J 2000, 19:2046-2055.
61. Han M, Sayed D, He M, Abdellatif M. miRNA-26 plays essential role in myocyte survival and hypertrophy by regulating GATA4. Circulation 2009, 120:S732.
62. Chan JA, Krichevsky AM, Kosik KS. microRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 2005, 65:6029-6033.
63. Cheng AM, Byrom MW, Shelton J, Ford LP. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res 2005, 33:1290-1297.
64. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene 2007, 26: 2799-2803.
65. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456:980-984.
66. Haghikia A, Hilfiker-Kleiner D. miRNA-21: a key to controlling the cardiac fibroblast compartment? Cardiovasc Res 2009, 82:1-3.
67. Roy S, Khanna S, Hussain SRA, Biswas S, Azad A, Rink C, Gnyawali S, Shilo S, Nuovo GJ, Sen CK, et al. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res 2009, 82:21-29.
68. Miano JM, Ramanan N, Georger MA, Bentley KLD, Emerson RL, Balza RO, Qi X, Weiler H, Ginty DD, Misra RP, et al. Restricted inactivation of serum response factor to the cardiovascular system. Proc Natl Acad Sci U S A 2004, 101:17132-17137.
69. Miralles F, Posern G, Zaromytidou AI, Treisman R. Actin dynamics control SRF activity by regulation of its coactivator MAL. Cell 2003, 113:329-342.
70. Norman C, Runswick M, Pollock R, Treisman R. Isolation and properties of cDNA clones encoding SRF, a transcription factor that binds to the c-fos serum response element. Cell 1988, 55:989-1003.
71. Wang ZG, Wang DZ, Hockemeyer D, McAnally J, Nordheim A, Olson EN. Myocardin and ternary complex factors compete for SRF to control smooth muscle gene expression. Nature 2004, 428:185-189.
72. Zhang X, Azhar G, Chai J, Sheridan P, Nagano K, Brown T, Yang J, Khrapko K, Borras AM, Lawitts J, et al. Cardiomyopathy in transgenic mice with cardiac-specific overexpression of serum response factor. Am J Physiol Heart Circ Physiol 2001, 280:H1782-H1792.
73. Zhang X, Chai J, Azhar G, Sheridan P, Borras AM, Furr MC, Khrapko K, Lawitts J, Misra RP, Wei JY, et al. Early postnatal cardiac changes and premature death in transgenic mice overexpressing a mutant form of serum response factor. J Biol Chem 2001, 276:40033-40040.
74. Ai J, Zhang R, Li Y, Pu JL, Lu YJ, Jiao JD, Li K, Yu B, Li ZQ, Wang RR, et al. Circulating microRNA-1 as a potential novel biomarker for acute myocardial infarction. Biochem Biophys Res Commun 2009, 391:73-77.
75. Ji X, Takahashi R, Hiura Y, Hirokawa G, Fukushima Y, Iwai N. Plasma miR-208 as a biomarker of myocardial injury. Clin Chem 2009, 55:1944-1949.
76. Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, Pinto YM. miR423-5p as a circulating biomarker for heart failure. Circ Res 2010, 106: 1035-1039.
77. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, Watts L, Booten SL, Graham M, McKay R, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006, 3:87-98.
78. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005, 438:685-689.